Lercanidipina Alter

Lercanidipine, the active ingredient in Lercanidipina Alter, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Lercanidipina Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured batches that meet EU regulatory standards for distribution across global markets. The company provides comprehensive logistics support, regulatory documentation, and timely delivery to facilitate import and local compliance.

Lercanidipine is used to treat hypertension, a condition characterized by chronically elevated arterial pressure. - Essential hypertension: reduces both systolic and diastolic blood pressure to target levels. - Isolated systolic hypertension: provides arterial vasodilation that lowers high systolic readings. - Secondary hypertension (e.g., renovascular): used as adjunct therapy to help control blood pressure.

Lercanidipine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache occurring after initiation. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or airway requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure leading to fainting or shock. - Hepatic dysfunction: abnormal liver enzyme elevations or hepatitis.

When prescribing lercanidipine, clinicians should consider several precautionary measures to ensure safe use. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: use with caution in patients with liver dysfunction. - Concomitant antihypertensives: evaluate risk of additive blood pressure lowering. - Sudden discontinuation: avoid abrupt stopping to prevent rebound hypertension. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels and risk of hypotension. - Grapefruit juice: can markedly raise lercanidipine concentrations. - Other potent vasodilators (e.g., nitroglycerin): may cause additive hypotensive effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug exposure and effectiveness. - Diuretics: may enhance blood pressure lowering, requiring dose adjustment. - Beta‑blockers: combined use may increase risk of bradycardia or excessive blood pressure reduction.